Received Nov 14, 2025
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Rash; This non-serious case was reported by a consumer and described the occurrence of rash in a 77-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included valaciclovir hydrochloride (Valacyclovir). On 31-OCT-2025, the patient received Shingrix. On 03-NOV-2025, 3 days after receiving Shingrix, the patient experienced rash (Verbatim: Rash). The outcome of the rash was resolving. It was unknown if the reporter considered the rash to be related to Shingrix. It was unknown if the company considered the rash to be related to Shingrix. Additional Information: GSK receipt Date: 06-NOV-2025 Patient had rash.
VALACYCLOVIR